BILL NUMBER: S6180

SPONSOR: LANZA
 
TITLE OF BILL:

An act to amend the insurance law, in relation to the use of abuse-det-
errent technology for opioids as a mechanism for reducing abuse and
diversion of opioid drugs

 
PURPOSE OR GENERAL IDEA OF BILL:

To help prevent the abuse and diversion of opioid analgesic drugs by
ensuring that abuse-deterrent drugs approved by the FDA are accessible
to patients and that that insurance coverage does not disadvantage
access for patients to drugs approved by the FDA as abuse-deterrent.

 
SUMMARY OF SPECIFIC PROVISIONS:

Section 1 adds a new section 3216-a to the insurance law to ensure
patient access to abuse-deterrent opioid analgesic drugs by requiring
that a minimum of one opioid abuse-deterrent opioid analgesic drug per
              

opioid analgesic active ingredient is covered by insurance plans and to
ensure that a patient is not required to take a non-abuse deterrent
opioid before an abuse-deterrent opioid version.

Section 2 is the effective date of the bill.

 
JUSTIFICATION:

While pain management is an important and integral part of the health
care system, abuse and diversion of opioids has necessitated the imple-
mentation of various anti-abuse policies. These policies need to be
approached comprehensively by government, law enforcement, health care
providers and manufacturers and an important component is to ensure that
opioids incorporating abuse-deterrent technologies are dispensed whenev-
er possible.

The U.S. Food and Drug Administration (FDA) has recognized that the
development and implementation of abuse-deterrent technologies is an
important "step towards the goal of creating safer opioid analgesics."
In recently published FDA guidance on abuse-deterrent technologies for
opioids, the FDA provided that they "consider the development of these
products a high public health-priority."  To combat opioid misuse and
abuse, the FDA is encouraging manufacturers to develop abuse-deterrent
formulations that when taken as prescribed still provide appropriate
pain relief, but are-formulated to make it more difficult to alter the
drug product for purposes of misuse or abuse, such as making the product
harder to crush or liquefy in order to snort or inject. The FDA has
provided guidance as to the steps that a manufacturer can take to demon-
strate that an opioid drug product is formulated with abuse-deterrent
technologies and after rigorous testing has shown that the abuse-deter-
rent formulation is expected to deter or reduce abuse of the drug prod-
uct. It is only after achieving successful results on these tests that
the FDA will allow for a drug product's label to include claims based on
demonstration of meaningful abuse-deterrent properties.

This proposal recognizes that to further the goal of encouraging the use
of abuse-deterrent technologies as part of a broader plan to reduce
opioid addiction and abuse, it is imperative that insurance coverage is
applied equitably and does not provide a disincentive to the use of
abuse-deterrent opioids.  This will help advance safe patient care by
ensuring that abuse-deterrent versions of available opioid analgesic
drug products are covered, including those containing nonopioid drug
substances to form a single drug product.

While New York State has been at the forefront of fighting prescription
drug abuse, it is critical that the State continue to strengthen its
laws and protect against abuse while enhancing the integrity of its
health care system. Enacting this proposal will be consistent with these
goals and with the priorities set out by the FDA.

 
PRIOR LEGISLATIVE HISTORY:

2020: S.3272 Referred to Insurance

2019: S.3272 - Referred to Insurance

2018: S.7009 Referred to Insurance / A.7999 - Referred to Insurance

2017: A.7999 - Referred to Insurance

 
FISCAL IMPLICATIONS:

None.

 
EFFECTIVE DATE:
This act shall take effect on the 120th day, and shall apply to all
policies and contracts issued, renewed, modified, altered or amended on
NEW YORK STATE SENATE INTRODUCER'S MEMORANDUM IN SUPPORT submitted in
accordance with Senate Rule VI. Sec 1